Tag: Phase III Trial

AR101

Aimmune Issues Update on AR101 Peanut Oral Immunotherapy Candidate

The company announces their timeline for continued progress toward an FDA approved standardized therapy.
DBV Patch Closeup

Positive Safety Results Reported for Viaskin Peanut Phase III Trial

The trial met its primary objective, demonstrating that Viaskin Peanut was well-tolerated with no new or unexpected adverse events.

Viaskin Peanut Phase III Trial Falls Short, Still Chance for FDA...

The Viaskin Peanut patch therapy still has 50:50 chance of approval according to research note.
Peanut Therapy

Aimmune, Regeneron and Sanofi Collaborate on Combination Peanut Therapy

More exciting news as pharma companies work to extend the effectiveness of their therapies in combination.
AR101

Aimmune Begins Patient Enrollment for Phase III Clinical Trial of Peanut...

First of 440 patients enrolled in study of AR101.
Viaskin Peanut

Peanut Patch Phase III Enrollment Ends, Results Expected Toward End of...

The study received higher-than-expected patient demand.

Connect with Us

30,003FansLike
89FollowersFollow
4,480FollowersFollow
33SubscribersSubscribe